ArticleBMC research notes2025
Analysis of the first inpatient expenditure for cervical cancer patients before and during the COVID-19 pandemic in a provincial maternal and children care hospital in China.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCOVID-19 has led to economic difficulties for many cancer patients. This study aimed to identify the trend and the major cost items of inpatient expenditure for the admittance to hospital for cervical cancer patients in Hunan Province Maternal and Children Care Hospital from 2017 to 2021.
methodsThis study assessed the composition of inpatient expenditure using the gray correlation method and the variation in the hospitalization expense structure using the degree of structural variation.
resultsA total of 909 patients were identified. The median age of the patients was 49±10.25 years. Insurance payments for cancer patients accounted for 33.51% before the COVID-19 pandemic (2017-2019) but increased to 80.29% during the pandemic (2020-2021). Diagnosis costs accounted for the largest proportion of medical expenditure every year and showed an increasing trend during the study period. Although the consumables cost accounted for the lowest proportion of total costs each year, they showed a fluctuating growth trend with an average annual growth rate of 23.54%, which was the only fluctuation cost of the six constituents. Drug cost had the only positive value for the structural variation of total medical expenditure over the five years.
conclusionsThe proportion of hospitalization expenses paid by insurance after COVID-19 is higher than that paid before COVID-19. Attention should be paid to the rising costs of drugs after the COVID-19 pandemic and reasonable control should be maintained for the diagnosis costs to reduce the total expenditure on cervical cancer patients after COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.